Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-03-20
2007-03-20
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S235100, C424S234100, C424S167100, C424S184100, C424S239100, C424S164100, C530S300000, C530S350000, C530S825000
Reexamination Certificate
active
10241596
ABSTRACT:
A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as abotulinumor tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
REFERENCES:
patent: 4594336 (1986-06-01), Bizzini
patent: 5668255 (1997-09-01), Murphy
patent: 5919665 (1999-07-01), Williams
patent: 5989545 (1999-11-01), Foster et al.
patent: 6043042 (2000-03-01), Shone et al.
patent: 6372225 (2002-04-01), Matsuda
patent: 6395513 (2002-05-01), Foster et al.
patent: 6444209 (2002-09-01), Johnson et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6776990 (2004-08-01), Sachs et al.
patent: 6787517 (2004-09-01), Gil et al.
patent: 6822076 (2004-11-01), Bigalke et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7081529 (2006-07-01), Smith et al.
patent: 2002/0044950 (2002-04-01), Shone et al.
patent: 2003/0049264 (2003-03-01), Foster et al.
patent: 2003/0147895 (2003-08-01), Shone et al.
patent: 2003/0166238 (2003-09-01), Shone et al.
patent: 2004/0013687 (2004-01-01), Simpson et al.
patent: 2004/0208889 (2004-10-01), Sutton et al.
patent: 2004/0219637 (2004-11-01), Williams
patent: 2005/0244435 (2005-11-01), Shone et al.
patent: 2006/0051356 (2006-03-01), Foster et al.
patent: 2006/0110410 (2006-05-01), Shone et al.
patent: 2006/0204524 (2006-09-01), Ichtchenko et al.
patent: 2006/0216283 (2006-09-01), Foster et al.
patent: WO 91/09871 (1991-07-01), None
patent: WO 92/15327 (1992-09-01), None
patent: WO 93/04191 (1993-03-01), None
patent: WO 93/15766 (1993-08-01), None
patent: WO 94/21300 (1994-09-01), None
patent: WO 94/21684 (1994-09-01), None
patent: WO 96/12802 (1996-05-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 2001/008390 (2001-01-01), None
patent: WO 02/44199 (2002-06-01), None
patent: WO 2004/024909 (2004-03-01), None
Binz et al, JBC, 1994, 269/3:1617-1620.
Tonello et al, Protein Expression and Purification, 1999, 15:221-227.
Chaddock et al, Protein Expression and Purification, 2002, 25:219-228.
Fujita et al, FEBS Letters, 1995, 376:41-44.
Lacy et al, Nature, 1998, 5/10:898-902.
Shone et al, Eur. J. Biochem., 1985, 151:75-82.
Schiavo et al, FEBS, Nov. 1993, 335/1:99-103.
Binz et al, JBC, 1990, 265/16:9153-9158.
Rigoni et al, BBRC, 2001, 288:1231-1237.
SAthyamoorthy et al, Archives of Biochemistry and Biophysics, 1988, 266/1:142-151.
Schmidt et al, BBRC, 1984, 119/3:900-904.
DasGupta et al, Biochimie, 1990, 72:661-664.
East et al, International J. Systematic Bacteriology, 1996, 46/4:1105-1112.
DasGupta et al, Biochemistry, 1987, 26:4162, Abstract #33 Abstract only.
Gimenez et al, J. Protein Chemistry, 1993, 12/3:351-363.
Betley et al, BBRC, 1989, 162/3:1388-1395.
Thompson et al, Eur. J. Biochem., 1990, 189:73-81.
Bowie et al, Science, 1990, 247:1306-1310.
Houghten et al, Vaccine86, 1986, pp. 21-25, editors:Brown et al.
Turton et al, TRENDS in Biochemical Sciences, Nov. 2002, 27/11:552-558.
Lalli et al, TRENDS in Microbiology, Sep. 2003, 11/9:431-437.
Montecucco et al, Molecular Medicine Today, Oct. 1996, pp. 418-424.
Johnson et al, Toxicon, 2001, 39:1703-1722.
Rossetto et al, Toxicon, 2001, 39:27-41.
Poulain, B., et al., “Inhibition of transmitter release by botulinum neurotoxin A: Contribution of various fragments to the intoxication process,”Eur. J. Biochem. 185: 197-203, Springer International (1989).
Rudinger J., “Characteristics of the amino acids as components of a peptide hormone sequence,” inPeptide Hormones, Parsons, J.A., ed., University Park Press, Baltimore, pp. 1-7 (1976).
Zhou, L., et al., “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain,”Biochem. 34:15175-15181, American Chemical Society (1995).
Kurazono, H., et al., “Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A,”J. Biol. Chem. 267:14721-14729, American Society for Biochemistry and Molecular Biology, Inc. (1992).
Li, Y., et al., “A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes its Proteolytic Activity and Removes the Toxicity Seen after Reconstitution with Native Heavy Chain,”Biochem. 33:7014-7020, American Chemical Society (1994).
Niemann, H., “Molecular Biology of Clostridial Neurotoxins,” InSourcebook of Bacterial Protein Toxins, Ch. 15, Alouf, J.E. and J.H. Freer, eds., Academic Press Limited, London, pp. 303-348 (1991).
Binz, T., et al., “The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neutoroxins,”J. Biol. Chem. 265:9153-9158, American Society for Biochemistry and Molecular Biology, Inc. (1990).
Bizzini, B., “Investigation of the Mode of Action of Tetanus Toxin with the Aid of Hybrid Molecules Consisting in Part of Tetanus Toxin-Derived Fragments,” inBacterial Protein Toxins, Academic Press London, pp. 427-434 (1984).
International Search Report for International Application No. PCT/GB97/02273, mailed Jan. 30, 1998.
Hausinger, A., et al., “Inhibition by Clostridial Neurotoxins of Calcium-Independent [3H] Noradrenaline Outflow from Freeze-Thawed Synaptosomes: Comparison with Synaptobrevin Hydrolysis,”Toxicon 33:1519-1530, Elsevier Science Ltd. (1995).
Application and Prosecution History for “Recombinant Toxin Fragments,” Shone et al., U.S. Appl. No. 09/255,829, filed Feb. 23, 1999.
Application and Prosecution History for “Conjugates of Galatose-Binding Lectins and Clostridial Neurotoxins as Analgesics,” Duggan et al., U.S. Appl. No. 09/529,130, with a §371 date Jun. 22, 2000.
Application and Prosecution History for “Methods and Compounds for the Treatment of Mucus Hypersecretion,” Quinn et al., U.S. Appl. No. 09/763,669, with a §371 date May 29, 2001.
Application and Prosecution History for “Delivery of Superoxide Dismutase to Neuronal Cells,” Shone et al., U.S. Appl. No. 09/831,050, with a §date of Aug. 20, 2001.
Application and Prosecution History for “Constructs for Delivery of Therapeutics Agents to Neuronal Cells,” Shone et al., U.S. Appl. No. 10/130,973, with a §371 date of Jun. 25, 2002.
Application and Prosecution History for “Methods and Compounds for the Treatment of Mucus Hypersecretion,” Quinn et al., U.S. Appl. No. 10/633,698, filed Aug. 5, 2003.
Shone et al., “Delivery of Superoxide Dismutase to Neuronal Cells,” U.S. Appl. No. 11/062,471, filed Feb. 22, 2005.
Shone et al., “Recombinant Toxin Fragments,” U.S. Appl. No. 11/077,550, filed Mar. 11, 2005.
Shone et al., “Recombinant Toxin Fragments,” U.S. Appl. No. 10/527,411, filed Mar. 11, 2005.
Chaddock John
Foster Keith Alan
Marks Philip
Quinn Conrad Padraig
Shone Clifford Charles
Minnifield N. M.
Sterne Kessler Goldstein & Fox P.L.L.C.
The Health Protection Agency Ipsen Limited
LandOfFree
Recombinant toxin fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant toxin fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant toxin fragments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3780599